{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T01:09:40Z","timestamp":1778029780329,"version":"3.51.4"},"publisher-location":"Cham","reference-count":117,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783032091321","type":"print"},{"value":"9783032091338","type":"electronic"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1007\/7854_2024_564","type":"book-chapter","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T08:35:59Z","timestamp":1735547759000},"page":"433-454","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Use of Cannabis-Based Medicine in Selected Neurological Disorders"],"prefix":"10.1007","author":[{"given":"Natalia","family":"Szejko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamila","family":"Saramak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten R.","family":"M\u00fcller-Vahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,31]]},"reference":[{"key":"564_CR1","doi-asserted-by":"publisher","unstructured":"Abate G, Uberti D, Tambaro S (2021) Potential and limits of cannabinoids in Alzheimer\u2019s disease therapy. Biology (Basel) 10. https:\/\/doi.org\/10.3390\/BIOLOGY10060542","DOI":"10.3390\/BIOLOGY10060542"},{"key":"564_CR2","doi-asserted-by":"publisher","unstructured":"Abi-Jaoude E, Chen L, Cheung P et al (2017) Preliminary evidence on cannabis effectiveness and tolerability for adults with Tourette syndrome. J Neuropsychiatry Clin Neurosci. https:\/\/doi.org\/10.1176\/appi.neuropsych.16110310","DOI":"10.1176\/appi.neuropsych.16110310"},{"key":"564_CR3","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1089\/CAN.2022.0091","volume":"8","author":"E Abi-Jaoude","year":"2023","unstructured":"Abi-Jaoude E, Bhikram T, Parveen F et al (2023) A double-blind, randomized, controlled crossover trial of Cannabis in adults with Tourette syndrome. Cannabis Cannabinoid Res. https:\/\/home.liebertpub.com\/can 8:835\u2013845. https:\/\/doi.org\/10.1089\/CAN.2022.0091","journal-title":"Cannabis Cannabinoid Res"},{"key":"564_CR4","doi-asserted-by":"publisher","unstructured":"Anis S, Zalomek C, Korczyn AD et al (2022) Medical Cannabis for Gilles de la Tourette syndrome: an open-label prospective study. Behav Neurol. https:\/\/doi.org\/10.1155\/2022\/5141773","DOI":"10.1155\/2022\/5141773"},{"key":"564_CR5","doi-asserted-by":"publisher","unstructured":"Anis S, Faust-Socher A, Sverdlov D et al (2023) A single-center real-life study on the use of medical cannabis in patients with dystonia. Front Neurol 14. https:\/\/doi.org\/10.3389\/FNEUR.2023.1218300","DOI":"10.3389\/FNEUR.2023.1218300"},{"key":"564_CR6","doi-asserted-by":"publisher","unstructured":"Baban B, Khodadadi H, Salles \u00c9L et al (2021) Inflammaging and Cannabinoids. Ageing Res Rev 72. https:\/\/doi.org\/10.1016\/J.ARR.2021.101487","DOI":"10.1016\/J.ARR.2021.101487"},{"key":"564_CR7","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/WNF.0000000000000246","volume":"40","author":"Y Balash","year":"2017","unstructured":"Balash Y, Bar-Lev Schleider L, Korczyn AD et al (2017) Medical Cannabis in Parkinson disease: real-life patients\u2019 experience. Clin Neuropharmacol 40:268\u2013272. https:\/\/doi.org\/10.1097\/WNF.0000000000000246","journal-title":"Clin Neuropharmacol"},{"key":"564_CR8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1089\/CAN.2022.0112","volume":"9","author":"D Barchel","year":"2024","unstructured":"Barchel D, Stolar O, Ziv-Baran T et al (2024) Use of medical cannabis in patients with Gilles de la Tourette\u2019s syndrome in a real-world setting. Cannabis Cannabinoid Res 9:293\u2013299. https:\/\/doi.org\/10.1089\/CAN.2022.0112","journal-title":"Cannabis Cannabinoid Res"},{"key":"564_CR9","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.biopsych.2004.01.005","volume":"55","author":"G Berding","year":"2004","unstructured":"Berding G, M\u00fcller-Vahl K, Schneider U et al (2004) [123I]AM281 single-photon emission computed tomography imaging of central cannabinoid CB1 receptors before and after \u03949-tetrahydrocannabinol therapy and whole-body scanning for assessment of radiation dose in Tourette patients. Biol Psychiatry 55:904\u2013915. https:\/\/doi.org\/10.1016\/j.biopsych.2004.01.005","journal-title":"Biol Psychiatry"},{"key":"564_CR10","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1176\/APPI.NEUROPSYCH.19080178","volume":"33","author":"MH Bloch","year":"2021","unstructured":"Bloch MH, Landeros-Weisenberger A, Johnson JA, Leckman JF (2021) A Phase-2 pilot study of a therapeutic combination of \u03949-tetrahydracannabinol and palmitoylethanolamide for adults with Tourette\u2019s syndrome. J Neuropsychiatry Clin Neurosci 33:328\u2013336. https:\/\/doi.org\/10.1176\/APPI.NEUROPSYCH.19080178","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"564_CR11","doi-asserted-by":"publisher","unstructured":"Bosnjak Kuharic D, Markovic D, Brkovic T et al (2021) Cannabinoids for the treatment of dementia. Cochrane Database Syst Rev 9. https:\/\/doi.org\/10.1002\/14651858.CD012820.PUB2","DOI":"10.1002\/14651858.CD012820.PUB2"},{"key":"564_CR12","doi-asserted-by":"publisher","unstructured":"Broers B, Bianchi F (2023) Cannabinoids for behavioral symptoms in dementia: an overview. Pharmacopsychiatry. https:\/\/doi.org\/10.1055\/A-2262-7837\/BIB","DOI":"10.1055\/A-2262-7837\/BIB"},{"key":"564_CR13","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1212\/01.WNL.0000140288.48796.8E","volume":"63","author":"CB Carroll","year":"2004","unstructured":"Carroll CB, Bain PO, Teare L et al (2004) Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology 63:1245\u20131250. https:\/\/doi.org\/10.1212\/01.WNL.0000140288.48796.8E","journal-title":"Neurology"},{"key":"564_CR14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2967\/JNUMED.118.210393","volume":"60","author":"J Ceccarini","year":"2019","unstructured":"Ceccarini J, Ahmad R, Van De Vliet L et al (2019) Behavioral symptoms in Premanifest Huntington disease correlate with reduced frontal CB1R levels. J Nucl Med 60:115\u2013121. https:\/\/doi.org\/10.2967\/JNUMED.118.210393","journal-title":"J Nucl Med"},{"key":"564_CR15","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/JCPT.12179","volume":"39","author":"MHN Chagas","year":"2014","unstructured":"Chagas MHN, Eckeli AL, Zuardi AW et al (2014a) Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson\u2019s disease patients: a case series. J Clin Pharm Ther 39:564\u2013566. https:\/\/doi.org\/10.1111\/JCPT.12179","journal-title":"J Clin Pharm Ther"},{"key":"564_CR16","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1177\/0269881114550355","volume":"28","author":"MHN Chagas","year":"2014","unstructured":"Chagas MHN, Zuardi AW, Tumas V et al (2014b) Effects of cannabidiol in the treatment of patients with Parkinson\u2019s disease: an exploratory double-blind trial. J Psychopharmacol 28:1088\u20131092. https:\/\/doi.org\/10.1177\/0269881114550355","journal-title":"J Psychopharmacol"},{"key":"564_CR17","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/0091-3057(91)90386-G","volume":"40","author":"P Consroe","year":"1991","unstructured":"Consroe P, Laguna J, Allender J et al (1991) Controlled clinical trial of cannabidiol in Huntington\u2019s disease. Pharmacol Biochem Behav 40:701\u2013708. https:\/\/doi.org\/10.1016\/0091-3057(91)90386-G","journal-title":"Pharmacol Biochem Behav"},{"key":"564_CR18","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1176\/JNP.2006.18.4.553","volume":"18","author":"A Curtis","year":"2006","unstructured":"Curtis A, Rickards H (2006) Nabilone could treat chorea and irritability in Huntington\u2019s disease. J Neuropsychiatry Clin Neurosci 18:553\u2013554. https:\/\/doi.org\/10.1176\/JNP.2006.18.4.553","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"564_CR19","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1002\/MDS.22809","volume":"24","author":"A Curtis","year":"2009","unstructured":"Curtis A, Mitchell I, Patel S et al (2009) A pilot study using nabilone for symptomatic treatment in Huntington\u2019s disease. Mov Disord 24:2254\u20132259. https:\/\/doi.org\/10.1002\/MDS.22809","journal-title":"Mov Disord"},{"key":"564_CR20","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1089\/CAN.2021.0158","volume":"8","author":"CMO De Almeida","year":"2023","unstructured":"De Almeida CMO, Brito MMC, Bosaipo NB et al (2023) The effect of Cannabidiol for restless legs syndrome\/Willis-Ekbom disease in Parkinson\u2019s disease patients with REM sleep behavior disorder: a post hoc exploratory analysis of phase 2\/3 clinical trial. Cannabis Cannabinoid Res 8:374\u2013378. https:\/\/doi.org\/10.1089\/CAN.2021.0158","journal-title":"Cannabis Cannabinoid Res"},{"key":"564_CR21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1177\/0269881119895536","volume":"34","author":"SM de Faria","year":"2020","unstructured":"de Faria SM, de Morais FD, Tumas V et al (2020) Effects of acute cannabidiol administration on anxiety and tremors induced by a simulated public speaking test in patients with Parkinson\u2019s disease. J Psychopharmacol 34:189\u2013196. https:\/\/doi.org\/10.1177\/0269881119895536","journal-title":"J Psychopharmacol"},{"key":"564_CR22","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1152\/PHYSREV.00049.2021","volume":"104","author":"O Devinsky","year":"2024","unstructured":"Devinsky O, Jones NA, Cunningham MO et al (2024) Cannabinoid treatments in epilepsy and seizure disorders. Physiol Rev 104:591\u2013649. https:\/\/doi.org\/10.1152\/PHYSREV.00049.2021","journal-title":"Physiol Rev"},{"key":"564_CR23","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/MDC3.13754","volume":"10","author":"DG Di Luca","year":"2023","unstructured":"Di Luca DG, Gilmour GS, Fearon C et al (2023) A phase Ib, double blind, randomized study of cannabis oil for pain in Parkinson\u2019s disease. Mov Disord Clin Pract 10:1114\u20131119. https:\/\/doi.org\/10.1002\/MDC3.13754","journal-title":"Mov Disord Clin Pract"},{"key":"564_CR24","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1002\/MDS.29447","volume":"38","author":"CH Domen","year":"2023","unstructured":"Domen CH, Sillau S, Liu Y et al (2023) Cognitive safety data from a randomized, double-blind, parallel-group, placebo-controlled phase IIb study of the effects of a Cannabidiol and \u03949-tetrahydrocannabinol drug on Parkinson\u2019s disease-related motor symptoms. Mov Disord 38:1341\u20131346. https:\/\/doi.org\/10.1002\/MDS.29447","journal-title":"Mov Disord"},{"key":"564_CR25","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1016\/j.cub.2014.08.038","volume":"24","author":"A Draper","year":"2014","unstructured":"Draper A, Stephenson MC, Jackson GM et al (2014) Increased GABA contributes to enhanced control over motor excitability in Tourette syndrome. Curr Biol 24:2343\u20132347. https:\/\/doi.org\/10.1016\/j.cub.2014.08.038","journal-title":"Curr Biol"},{"key":"564_CR26","doi-asserted-by":"publisher","unstructured":"Ellmerer P, Peball M, Carbone F et al (2022) Eye tracking in patients with Parkinson\u2019s disease treated with Nabilone-results of a phase II, placebo-controlled, double-blind. Parallel-Group Pilot Study Brain Sci:12. https:\/\/doi.org\/10.3390\/BRAINSCI12050661","DOI":"10.3390\/BRAINSCI12050661"},{"key":"564_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/0269881112460109","volume":"27","author":"A Englund","year":"2013","unstructured":"Englund A, Morrison PD, Nottage J et al (2013) Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol 27:19\u201327. https:\/\/doi.org\/10.1177\/0269881112460109","journal-title":"J Psychopharmacol"},{"key":"564_CR28","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/ANE.13602","volume":"145","author":"AH Erga","year":"2022","unstructured":"Erga AH, Maple-Gr\u00f8dem J, Alves G (2022) Cannabis use in Parkinson\u2019s disease \u2013 a nationwide online survey study. Acta Neurol Scand 145:692\u2013697. https:\/\/doi.org\/10.1111\/ANE.13602","journal-title":"Acta Neurol Scand"},{"key":"564_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.5603\/PJNNS.A2022.0004","volume":"56","author":"M Figura","year":"2022","unstructured":"Figura M, Koziorowski D, S\u0142awek J (2022) Cannabis in Parkinson\u2019s disease \u2013 the patient\u2019s perspective versus clinical trials: a systematic literature review. Neurol Neurochir Pol 56:21\u201327. https:\/\/doi.org\/10.5603\/PJNNS.A2022.0004","journal-title":"Neurol Neurochir Pol"},{"key":"564_CR30","doi-asserted-by":"publisher","unstructured":"Finseth TA, Hedeman JL, Brown RP et al (2015) Self-reported efficacy of cannabis and other complementary medicine modalities by Parkinson\u2019s disease patients in Colorado. Evid Based Complement Alternat Med 2015. https:\/\/doi.org\/10.1155\/2015\/874849","DOI":"10.1155\/2015\/874849"},{"key":"564_CR31","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/MDS.1280","volume":"17","author":"SH Fox","year":"2002","unstructured":"Fox SH, Kellett M, Moore AP et al (2002) Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov Disord 17:145\u2013149. https:\/\/doi.org\/10.1002\/MDS.1280","journal-title":"Mov Disord"},{"key":"564_CR32","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1212\/01.WNL.0000118203.67138.3E","volume":"62","author":"P Fox","year":"2004","unstructured":"Fox P, Bain PG, Glickman S et al (2004) The effect of cannabis on tremor in patients with multiple sclerosis. Neurology 62:1105\u20131109. https:\/\/doi.org\/10.1212\/01.WNL.0000118203.67138.3E","journal-title":"Neurology"},{"key":"564_CR33","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1080\/14737175.2020.1776610","volume":"20","author":"YD Fragoso","year":"2020","unstructured":"Fragoso YD, Carra A, Macias MA (2020) Cannabis and multiple sclerosis. Expert Rev Neurother 20:849\u2013854. https:\/\/doi.org\/10.1080\/14737175.2020.1776610","journal-title":"Expert Rev Neurother"},{"key":"564_CR34","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1111\/BCP.13020","volume":"82","author":"L Gabrielsson","year":"2016","unstructured":"Gabrielsson L, Mattsson S, Fowler CJ (2016) Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. Br J Clin Pharmacol 82:932\u2013942. https:\/\/doi.org\/10.1111\/BCP.13020","journal-title":"Br J Clin Pharmacol"},{"key":"564_CR35","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1006\/mcpr.1999.0249","volume":"13","author":"D Gadzicki","year":"1999","unstructured":"Gadzicki D, M\u00fcller-Vahl K, Stuhrmann M (1999) A frequent polymorphism in the coding exon of the human cannabinoid receptor (CNR1) gene. Mol Cell Probes 13:321\u2013323. https:\/\/doi.org\/10.1006\/mcpr.1999.0249","journal-title":"Mol Cell Probes"},{"key":"564_CR36","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/S11325-019-01978-1","volume":"24","author":"I Ghorayeb","year":"2020","unstructured":"Ghorayeb I (2020) More evidence of cannabis efficacy in restless legs syndrome. Sleep Breath 24:277\u2013279. https:\/\/doi.org\/10.1007\/S11325-019-01978-1","journal-title":"Sleep Breath"},{"key":"564_CR37","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0306-4522(00)00008-7","volume":"97","author":"M Glass","year":"2000","unstructured":"Glass M, Dragunow M, Faull RLM (2000) The pattern of neurodegeneration in Huntington\u2019s disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington\u2019s disease. Neuroscience 97:505\u2013519. https:\/\/doi.org\/10.1016\/S0306-4522(00)00008-7","journal-title":"Neuroscience"},{"key":"564_CR38","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s00415-011-6171-1","volume":"259","author":"A Hartmann","year":"2012","unstructured":"Hartmann A, Worbe Y, Arnulf I (2012) Increasing histamine neurotransmission in Gilles de la Tourette syndrome. J Neurol 259:375\u2013376","journal-title":"J Neurol"},{"key":"564_CR39","doi-asserted-by":"publisher","unstructured":"Hazekamp A, Ware MA, Muller-Vahl KR, et al (2013) The medicinal use of cannabis and cannabinoids--an international cross-sectional survey on administration forms. J Psychoactive Drugs 45:199\u2013210. https:\/\/doi.org\/10.1080\/02791072.2013.805976","DOI":"10.1080\/02791072.2013.805976"},{"key":"564_CR40","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1177\/026988119300700411","volume":"7","author":"M Hemming","year":"1993","unstructured":"Hemming M, Yellowlees PM (1993) Effective treatment of Tourette\u2019s syndrome with marijuana. J Psychopharmacol 7:389\u2013391. https:\/\/doi.org\/10.1177\/026988119300700411","journal-title":"J Psychopharmacol"},{"key":"564_CR41","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/S00702-023-02719-1","volume":"131","author":"U Hidding","year":"2024","unstructured":"Hidding U, Mainka T, Buhmann C (2024) Therapeutic use of medical Cannabis in neurological diseases: a clinical update. J Neural Transm (Vienna) 131:117\u2013126. https:\/\/doi.org\/10.1007\/S00702-023-02719-1","journal-title":"J Neural Transm (Vienna)"},{"key":"564_CR42","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/J.NEUROBIOLAGING.2019.03.008","volume":"79","author":"EL Hodges","year":"2019","unstructured":"Hodges EL, Ashpole NM (2019) Aging circadian rhythms and cannabinoids. Neurobiol Aging 79:110\u2013118. https:\/\/doi.org\/10.1016\/J.NEUROBIOLAGING.2019.03.008","journal-title":"Neurobiol Aging"},{"key":"564_CR43","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/MDC3.13414","volume":"9","author":"SK Holden","year":"2022","unstructured":"Holden SK, Domen CH, Sillau S et al (2022) Higher risk, higher reward? Self-reported effects of real-world Cannabis use in Parkinson\u2019s disease. Mov Disord Clin Pract 9:340\u2013350. https:\/\/doi.org\/10.1002\/MDC3.13414","journal-title":"Mov Disord Clin Pract"},{"key":"564_CR44","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000503864","volume":"2","author":"AG Hounie","year":"2019","unstructured":"Hounie AG, Almeida Vasques MA (2019) Neurological improvement with medical Cannabis in a progressive Supranuclear Palsy patient: a case report. Med Cannabis Cannabinoids 2:65\u201368. https:\/\/doi.org\/10.1159\/000503864","journal-title":"Med Cannabis Cannabinoids"},{"key":"564_CR45","doi-asserted-by":"publisher","first-page":"10.1016\/J.FITOT","DOI":"10.1016\/j.fitote.2024.105883","volume":"175","author":"Y-K Jiang","year":"2024","unstructured":"Jiang Y-K, Mmeng L, Syi W et al (2024) Protective effect of phenylpropionamides in the seed of Cannabis Sativa L. on Parkinson\u2019s disease through autophagy. Fitoterapia 175:10.1016\/J.FITOTE.2024.105883","journal-title":"Fitoterapia"},{"key":"564_CR46","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/BRAIN\/AWW285","volume":"140","author":"AS Kanaan","year":"2017","unstructured":"Kanaan AS, Gerasch S, Garc\u00eda-Garc\u00eda I et al (2017) Pathological glutamatergic neurotransmission in Gilles de la Tourette syndrome. Brain 140:218\u2013234. https:\/\/doi.org\/10.1093\/BRAIN\/AWW285","journal-title":"Brain"},{"key":"564_CR47","doi-asserted-by":"publisher","first-page":"663","DOI":"10.25259\/JNRP-2022-6-19","volume":"13","author":"A Kanjanarangsichai","year":"2022","unstructured":"Kanjanarangsichai A, Mitarnun W, Mitarnun W et al (2022) Cannabidiol-enriched cannabis extraction product in Parkinson\u2019s disease: a randomized, double-blind, and placebo-controlled trial in Buriram Hospital. J Neurosci Rural Pract 13:663\u2013668. https:\/\/doi.org\/10.25259\/JNRP-2022-6-19","journal-title":"J Neurosci Rural Pract"},{"key":"564_CR48","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/J.CGER.2021.07.003","volume":"38","author":"R Khoury","year":"2022","unstructured":"Khoury R, Maliha P, Ibrahim R (2022) Cannabis use and misuse in older adults. Clin Geriatr Med 38:67\u201383. https:\/\/doi.org\/10.1016\/J.CGER.2021.07.003","journal-title":"Clin Geriatr Med"},{"key":"564_CR49","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/J.CTIM.2017.07.002","volume":"33","author":"JH Kindred","year":"2017","unstructured":"Kindred JH, Li K, Ketelhut NB et al (2017) Cannabis use in people with Parkinson\u2019s disease and multiple sclerosis: a web-based investigation. Complement Ther Med 33:99\u2013104. https:\/\/doi.org\/10.1016\/J.CTIM.2017.07.002","journal-title":"Complement Ther Med"},{"key":"564_CR50","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/J.PARKRELDIS.2022.08.014","volume":"102","author":"BM Kluger","year":"2022","unstructured":"Kluger BM, Huang AP, Miyasaki JM (2022) Cannabinoids in movement disorders. Parkinsonism Relat Disord 102:124\u2013130. https:\/\/doi.org\/10.1016\/J.PARKRELDIS.2022.08.014","journal-title":"Parkinsonism Relat Disord"},{"key":"564_CR51","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1097\/00001756-200305060-00007","volume":"14","author":"I Lastres-Becker","year":"2003","unstructured":"Lastres-Becker I, Bizat N, Boyer F et al (2003a) Effects of cannabinoids in the rat model of Huntington\u2019s disease generated by an intrastriatal injection of malonate. Neuroreport 14:813\u2013816. https:\/\/doi.org\/10.1097\/00001756-200305060-00007","journal-title":"Neuroreport"},{"key":"564_CR52","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1046\/j.1471-4159.2003.01595.x","volume":"84","author":"I Lastres-Becker","year":"2003","unstructured":"Lastres-Becker I, De Miguel R, De Petrocellis L et al (2003b) Compounds acting at the endocannabinoid and\/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington\u2019s disease. J Neurochem 84:1097\u20131109. https:\/\/doi.org\/10.1046\/j.1471-4159.2003.01595.x","journal-title":"J Neurochem"},{"key":"564_CR53","doi-asserted-by":"publisher","unstructured":"Liu Y, Bainbridge J, Sillau S et al (2024) Short-term Cannabidiol with \u0394-9-tetrahydrocannabinol in Parkinson\u2019s disease: a randomized trial. Mov Disord. https:\/\/doi.org\/10.1002\/MDS.29768","DOI":"10.1002\/MDS.29768"},{"key":"564_CR54","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1007\/S00415-016-8145-9","volume":"263","author":"JL L\u00f3pez-Send\u00f3n Moreno","year":"2016","unstructured":"L\u00f3pez-Send\u00f3n Moreno JL, Garc\u00eda Caldentey J, Trigo Cubillo P et al (2016) A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington\u2019s disease. J Neurol 263:1390\u20131400. https:\/\/doi.org\/10.1007\/S00415-016-8145-9","journal-title":"J Neurol"},{"key":"564_CR55","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/WNF.0000000000000016","volume":"37","author":"I Lotan","year":"2014","unstructured":"Lotan I, Treves TA, Roditi Y, Djaldetti R (2014) Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study. Clin Neuropharmacol 37:41\u201344. https:\/\/doi.org\/10.1097\/WNF.0000000000000016","journal-title":"Clin Neuropharmacol"},{"key":"564_CR56","doi-asserted-by":"publisher","unstructured":"Maia T v., Concei\u00e7\u00e3o VA (2018) Dopaminergic disturbances in Tourette syndrome: an integrative account. Biol Psychiatry 84:332\u2013344. https:\/\/doi.org\/10.1016\/J.BIOPSYCH.2018.02.1172","DOI":"10.1016\/J.BIOPSYCH.2018.02.1172"},{"key":"564_CR57","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/S10072-019-04196-5","volume":"41","author":"MM Mascia","year":"2020","unstructured":"Mascia MM, Carmagnini D, Defazio G (2020) Cannabinoids and dystonia: an issue yet to be defined. Neurol Sci 41:783\u2013787. https:\/\/doi.org\/10.1007\/S10072-019-04196-5","journal-title":"Neurol Sci"},{"key":"564_CR58","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/J.SLEEP.2017.04.019","volume":"36","author":"T Megelin","year":"2017","unstructured":"Megelin T, Ghorayeb I (2017) Cannabis for restless legs syndrome: a report of six patients. Sleep Med 36:182\u2013183. https:\/\/doi.org\/10.1016\/J.SLEEP.2017.04.019","journal-title":"Sleep Med"},{"key":"564_CR59","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/BF00314410","volume":"236","author":"HM Meinck","year":"1989","unstructured":"Meinck HM, Sch\u00f6nle PW, Conrad B (1989) Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol 236:120\u2013122. https:\/\/doi.org\/10.1007\/BF00314410","journal-title":"J Neurol"},{"key":"564_CR60","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1097\/00002826-200405000-00003","volume":"27","author":"V Mesnage","year":"2004","unstructured":"Mesnage V, Houeto JL, Bonnet AM et al (2004) Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease. Clin Neuropharmacol 27:108\u2013110. https:\/\/doi.org\/10.1097\/00002826-200405000-00003","journal-title":"Clin Neuropharmacol"},{"key":"564_CR61","doi-asserted-by":"publisher","unstructured":"Mestre TA, Jo\u00e3o Forjaz M, Mahlknecht P et al (2017) Rating scales for motor symptoms and signs in Huntington\u2019s disease: critique and recommendations. https:\/\/doi.org\/10.1002\/mdc3.12571","DOI":"10.1002\/mdc3.12571"},{"key":"564_CR62","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/J.PARKRELDIS.2020.06.033","volume":"78","author":"FE Micheli","year":"2020","unstructured":"Micheli FE, Groppo J, Contartese ML et al (2020) Cannabis in patients with Parkinson\u2019s disease in Argentina. A cross sectional study. Parkinsonism Relat Disord 78:66\u201367. https:\/\/doi.org\/10.1016\/J.PARKRELDIS.2020.06.033","journal-title":"Parkinsonism Relat Disord"},{"key":"564_CR63","doi-asserted-by":"publisher","unstructured":"Millman N, van der Woerd B, Sund LT, Johns M (2023) Cannabinoid use in the treatment of laryngeal dystonia and vocal tremor: a pilot investigation. J Voice 0. https:\/\/doi.org\/10.1016\/j.jvoice.2023.05.006","DOI":"10.1016\/j.jvoice.2023.05.006"},{"key":"564_CR64","doi-asserted-by":"publisher","unstructured":"Milosev LM, Psathakis N, Szejko N et al (2019) Treatment of Gilles de la Tourette syndrome with cannabis-based medicine: results from a retrospective analysis and online survey. Cannabis Cannabinoid Res 4. https:\/\/doi.org\/10.1089\/can.2018.0050","DOI":"10.1089\/can.2018.0050"},{"key":"564_CR65","doi-asserted-by":"publisher","unstructured":"Mosley PE, Webb L, Suraev A et al (2023) Tetrahydrocannabinol and Cannabidiol in Tourette syndrome. NEJM Evidence 2. https:\/\/doi.org\/10.1056\/EVIDOA2300012","DOI":"10.1056\/EVIDOA2300012"},{"key":"564_CR66","doi-asserted-by":"publisher","first-page":"312","DOI":"10.4140\/TCP.N.2020.312","volume":"35","author":"A Mueller","year":"2021","unstructured":"Mueller A, Fixen DR (2021) Use of cannabis for agitation in patients with dementia. Sr Care Pharm 35:312\u2013317. https:\/\/doi.org\/10.4140\/TCP.N.2020.312","journal-title":"Sr Care Pharm"},{"key":"564_CR67","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/j.1600-0447.1998.tb10127.x","volume":"98","author":"KRK Muller-Vahl","year":"1998","unstructured":"Muller-Vahl KRK (1998) Cannabinoids: possible role in patho-physiology and therapy of Gilles de la Tourette syndrome. Acta Psychiatr Scand 98:502\u2013506","journal-title":"Acta Psychiatr Scand"},{"issue":"Suppl 3","key":"564_CR68","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1159\/000057153","volume":"6","author":"KR Muller-Vahl","year":"1999","unstructured":"Muller-Vahl KR, Kolbe H, Schneider U, Emrich HM (1999) Cannabis in movement disorders. Forsch Komplementmed 6(Suppl 3):23\u201327. https:\/\/doi.org\/10.1159\/000057153","journal-title":"Forsch Komplementmed"},{"key":"564_CR69","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1002\/1531-8257(199911)14:6<1038::aid-mds1024>3.0.co;2-7","volume":"14","author":"KR M\u00fcller-Vahl","year":"1999","unstructured":"M\u00fcller-Vahl KR, Schneider U, Emrich HM (1999) Nabilone increases choreatic movements in Huntington\u2019s disease. Mov Disord 14:1038\u20131040. https:\/\/doi.org\/10.1002\/1531-8257(199911)14:6<1038::aid-mds1024>3.0.co;2-7","journal-title":"Mov Disord"},{"key":"564_CR70","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1055\/S-2002-25028\/ID\/24\/BIB","volume":"35","author":"KR M\u00fcller-Vahl","year":"2002","unstructured":"M\u00fcller-Vahl KR, Schneider U, Koblenz A et al (2002) Treatment of Tourette\u2019s syndrome with \u03949-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 35:57\u201361. https:\/\/doi.org\/10.1055\/S-2002-25028\/ID\/24\/BIB","journal-title":"Pharmacopsychiatry"},{"key":"564_CR71","doi-asserted-by":"publisher","first-page":"459","DOI":"10.4088\/JCP.V64N0417","volume":"64","author":"KR M\u00fcller-Vahl","year":"2003","unstructured":"M\u00fcller-Vahl KR, Schneider U, Prevedel H et al (2003) Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry 64:459\u2013465. https:\/\/doi.org\/10.4088\/JCP.V64N0417","journal-title":"J Clin Psychiatry"},{"key":"564_CR72","doi-asserted-by":"publisher","unstructured":"M\u00fcller-Vahl KR, Szejko N, Wilke F et al (2019) Serotonin transporter binding is increased in Tourette syndrome with obsessive compulsive disorder. Sci Rep 9. https:\/\/doi.org\/10.1038\/S41598-018-37710-4","DOI":"10.1038\/S41598-018-37710-4"},{"key":"564_CR73","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/s41386-020-0671-6","volume":"45","author":"KR M\u00fcller-Vahl","year":"2020","unstructured":"M\u00fcller-Vahl KR, Bindila L, Lutz B et al (2020) Cerebrospinal fluid endocannabinoid levels in Gilles de la Tourette syndrome. Neuropsychopharmacology 45:1323\u20131329. https:\/\/doi.org\/10.1038\/s41386-020-0671-6","journal-title":"Neuropsychopharmacology"},{"key":"564_CR74","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1002\/MDS.28681","volume":"36","author":"KR M\u00fcller-Vahl","year":"2021","unstructured":"M\u00fcller-Vahl KR, Fremer C, Beals C et al (2021) Monoacylglycerol lipase inhibition in Tourette syndrome: a 12-week, randomized, controlled study. Mov Disord 36:2413\u20132418. https:\/\/doi.org\/10.1002\/MDS.28681","journal-title":"Mov Disord"},{"key":"564_CR75","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1055\/A-1675-3494","volume":"55","author":"KR M\u00fcller-Vahl","year":"2022","unstructured":"M\u00fcller-Vahl KR, Fremer C, Beals C et al (2022a) Endocannabinoid modulation using Monoacylglycerol lipase inhibition in Tourette syndrome: a phase 1 randomized, placebo-controlled study. Pharmacopsychiatry 55:148\u2013156. https:\/\/doi.org\/10.1055\/A-1675-3494","journal-title":"Pharmacopsychiatry"},{"key":"564_CR76","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/S00787-021-01832-4","volume":"31","author":"KR M\u00fcller-Vahl","year":"2022","unstructured":"M\u00fcller-Vahl KR, Szejko N, Verdellen C et al (2022b) European clinical guidelines for Tourette syndrome and other tic disorders: summary statement. Eur Child Adolesc Psychiatry 31:377\u2013382. https:\/\/doi.org\/10.1007\/S00787-021-01832-4","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"564_CR77","doi-asserted-by":"publisher","unstructured":"M\u00fcller-Vahl KR, Pisarenko A, Szejko N et al (2023) CANNA-TICS: efficacy and safety of oral treatment with nabiximols in adults with chronic tic disorders \u2013 results of a prospective, multicenter, randomized, double-blind, placebo controlled, phase IIIb superiority study. Psychiatry Res:323. https:\/\/doi.org\/10.1016\/J.PSYCHRES.2023.115135","DOI":"10.1016\/J.PSYCHRES.2023.115135"},{"key":"564_CR78","doi-asserted-by":"publisher","unstructured":"M\u00fcller-Vahl KR, Pisarenko A, Ringlstetter R et al (2024) The effect of Nabiximols on driving ability in adults with chronic tic disorders: results of a substudy analysis of the double-blind, randomized, placebo-controlled CANNA-TICS trial. https:\/\/home.liebertpub.com\/can. https:\/\/doi.org\/10.1089\/CAN.2023.0114","DOI":"10.1089\/CAN.2023.0114"},{"key":"564_CR79","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/S00702-022-02529-X","volume":"129","author":"P Oikonomou","year":"2022","unstructured":"Oikonomou P, Jost WH (2022) Randomized controlled trials on the use of cannabis-based medicines in movement disorders: a systematic review. J Neural Transm (Vienna) 129:1247\u20131256. https:\/\/doi.org\/10.1007\/S00702-022-02529-X","journal-title":"J Neural Transm (Vienna)"},{"key":"564_CR80","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/J.BJANE.2021.06.018","volume":"72","author":"C Pantoja-Ruiz","year":"2022","unstructured":"Pantoja-Ruiz C, Restrepo-Jimenez P, Casta\u00f1eda-Cardona C et al (2022) Cannabis and pain: a scoping review. Braz J Anesthesiol 72:142\u2013151. https:\/\/doi.org\/10.1016\/J.BJANE.2021.06.018","journal-title":"Braz J Anesthesiol"},{"key":"564_CR81","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.2174\/138161208785740108","volume":"14","author":"M Pazos","year":"2008","unstructured":"Pazos M, Sagredo O, Fernandez-Ruiz J (2008) The endocannabinoid system in Huntingtons disease. Curr Pharm Des 14:2317\u20132325. https:\/\/doi.org\/10.2174\/138161208785740108","journal-title":"Curr Pharm Des"},{"key":"564_CR82","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/ANA.25864","volume":"88","author":"M Peball","year":"2020","unstructured":"Peball M, Krismer F, Knaus HG et al (2020) Non-motor symptoms in Parkinson\u2019s disease are reduced by Nabilone. Ann Neurol 88:712\u2013722. https:\/\/doi.org\/10.1002\/ANA.25864","journal-title":"Ann Neurol"},{"key":"564_CR83","doi-asserted-by":"publisher","unstructured":"Peres FF, Lima AC, Hallak JEC et al (2018) Cannabidiol as a promising strategy to treat and prevent movement disorders? Front Pharmacol 9. https:\/\/doi.org\/10.3389\/FPHAR.2018.00482","DOI":"10.3389\/FPHAR.2018.00482"},{"key":"564_CR84","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/ARCLIN\/ACAA105","volume":"36","author":"N Pocuca","year":"2021","unstructured":"Pocuca N, Walter TJ, Minassian A et al (2021) The effects of cannabis use on cognitive function in healthy aging: a systematic scoping review. Arch Clin Neuropsychol 36:673\u2013685. https:\/\/doi.org\/10.1093\/ARCLIN\/ACAA105","journal-title":"Arch Clin Neuropsychol"},{"key":"564_CR85","doi-asserted-by":"publisher","unstructured":"Pringsheim T, Okun MS, M\u00fcller-Vahl K et al (2019) Practice guideline recommendations summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000007466","DOI":"10.1212\/WNL.0000000000007466"},{"key":"564_CR86","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/01658107.2017.1318150","volume":"41","author":"PM Radke","year":"2017","unstructured":"Radke PM, Mokhtarzadeh A, Lee MS, Harrison AR (2017) Medical cannabis, a beneficial high in treatment of Blepharospasm? An early observation. Neuroophthalmology 41:253\u2013258. https:\/\/doi.org\/10.1080\/01658107.2017.1318150","journal-title":"Neuroophthalmology"},{"key":"564_CR87","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3233\/JHD-170283","volume":"7","author":"C Saft","year":"2018","unstructured":"Saft C, Von Hein SM, Lucke T et al (2018) Cannabinoids for treatment of dystonia in Huntington\u2019s disease. J Huntingtons Dis 7:167\u2013173. https:\/\/doi.org\/10.3233\/JHD-170283","journal-title":"J Huntingtons Dis"},{"key":"564_CR88","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/glia.20838","volume":"57","author":"O Sagredo","year":"2009","unstructured":"Sagredo O, Gonz\u00e1lez S, Aroyo I et al (2009) Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington\u2019s disease. Glia 57:1154\u20131167. https:\/\/doi.org\/10.1002\/glia.20838","journal-title":"Glia"},{"key":"564_CR89","doi-asserted-by":"publisher","unstructured":"Samaha D, Kandiah T, Zimmerman D (2020) Cannabis use for restless legs syndrome and uremic pruritus in in patients treated with maintenance dialysis: a survey. Can J Kidney Health Dis 7. https:\/\/doi.org\/10.1177\/2054358120954944","DOI":"10.1177\/2054358120954944"},{"key":"564_CR90","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1097\/00004714-198812000-00021","volume":"8","author":"R Sandyk","year":"1988","unstructured":"Sandyk R, Awerbuch G (1988) Marijuana and Tourette\u2019s syndrome. J Clin Psychopharmacol 8:444\u2013445. https:\/\/doi.org\/10.1097\/00004714-198812000-00021","journal-title":"J Clin Psychopharmacol"},{"key":"564_CR91","doi-asserted-by":"publisher","unstructured":"Saramak K, Szejko N, Saramak K, Szejko N (2022) Endocannabinoid system as a new therapeutic avenue for the treatment of Huntington\u2019s disease. From pathophysiology to treatment of Huntington\u2019s disease. https:\/\/doi.org\/10.5772\/INTECHOPEN.104566","DOI":"10.5772\/INTECHOPEN.104566"},{"key":"564_CR92","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/EJP.942","volume":"21","author":"A Shohet","year":"2017","unstructured":"Shohet A, Khlebtovsky A, Roizen N et al (2017) Effect of medical cannabis on thermal quantitative measurements of pain in patients with Parkinson\u2019s disease. Eur J Pain 21:486\u2013493. https:\/\/doi.org\/10.1002\/EJP.942","journal-title":"Eur J Pain"},{"key":"564_CR93","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1212\/WNL.57.11.2108","volume":"57","author":"KA Sieradzan","year":"2001","unstructured":"Sieradzan KA, Fox SH, Hill M et al (2001) Cannabinoids reduce levodopa-induced dyskinesia in Parkinson\u2019s disease: a pilot study. Neurology 57:2108\u20132111. https:\/\/doi.org\/10.1212\/WNL.57.11.2108","journal-title":"Neurology"},{"key":"564_CR94","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1167\/TVST.12.8.17","volume":"12","author":"RZ Silkiss","year":"2023","unstructured":"Silkiss RZ, Koppinger J, Truong T et al (2023) Cannabidiol as an adjunct to botulinum toxin in Blepharospasm \u2013 a randomized pilot study. Transl Vis Sci Technol 12:17\u201317. https:\/\/doi.org\/10.1167\/TVST.12.8.17","journal-title":"Transl Vis Sci Technol"},{"key":"564_CR95","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/HRP.0000000000000289","volume":"29","author":"HV Solomon","year":"2021","unstructured":"Solomon HV, Greenstein AP, Delisi LE (2021) Cannabis use in older adults: a perspective. Harv Rev Psychiatry 29:225\u2013233. https:\/\/doi.org\/10.1097\/HRP.0000000000000289","journal-title":"Harv Rev Psychiatry"},{"key":"564_CR96","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/BS.IRMVD.2021.11.003","volume":"3","author":"N Szejko","year":"2022","unstructured":"Szejko N (2022) Update and recent progress in the neurobiology of Tourette syndrome. Int Rev Mov Disord 3:131\u2013158. https:\/\/doi.org\/10.1016\/BS.IRMVD.2021.11.003","journal-title":"Int Rev Mov Disord"},{"key":"564_CR97","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/BS.IRMVD.2022.04.002","volume":"4","author":"N Szejko","year":"2022","unstructured":"Szejko N, M\u00fcller-Vahl K (2022) Cannabinoids: possible role in the pathophysiology and therapy of Gilles de la Tourette syndrome. Int Rev Mov Disord 4:269\u2013294. https:\/\/doi.org\/10.1016\/BS.IRMVD.2022.04.002","journal-title":"Int Rev Mov Disord"},{"key":"564_CR98","doi-asserted-by":"publisher","unstructured":"Szejko N, Jakubovski E, M\u00fcller-Vahl K et al (2018) Possible role of the endocannabinoid system in Tourette syndrome. Recent Adv Cannabinoid Res. https:\/\/doi.org\/10.5772\/INTECHOPEN.79895","DOI":"10.5772\/INTECHOPEN.79895"},{"key":"564_CR99","doi-asserted-by":"publisher","unstructured":"Szejko N, Fichna JP, Safranow K et al (2020) Association of a variant of CNR1 gene encoding cannabinoid receptor 1 with Gilles de la Tourette syndrome. Front Genet 11. https:\/\/doi.org\/10.3389\/FGENE.2020.00125","DOI":"10.3389\/FGENE.2020.00125"},{"key":"564_CR100","doi-asserted-by":"publisher","unstructured":"Szejko N, Burger F, Sidoroff V, Wenning GK (2021) Case report: secondary bilateral parkinsonism and dystonia treated with dronabinol. F1000Res 9. https:\/\/doi.org\/10.12688\/F1000RESEARCH.26476.3","DOI":"10.12688\/F1000RESEARCH.26476.3"},{"key":"564_CR101","doi-asserted-by":"publisher","unstructured":"Szejko N, Becher E, Heimann F et al (2024) Medicinal use of different cannabis strains: results from a large prospective survey in Germany. Pharmacopsychiatry. https:\/\/doi.org\/10.1055\/A-2261-2269","DOI":"10.1055\/A-2261-2269"},{"key":"564_CR102","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/J.PARKRELDIS.2018.10.004","volume":"61","author":"A Thaler","year":"2019","unstructured":"Thaler A, Arad S, Schleider LBL et al (2019) Single center experience with medical cannabis in Gilles de la Tourette syndrome. Parkinsonism Relat Disord 61:211\u2013213. https:\/\/doi.org\/10.1016\/J.PARKRELDIS.2018.10.004","journal-title":"Parkinsonism Relat Disord"},{"key":"564_CR103","doi-asserted-by":"publisher","unstructured":"Thanabalasingam SJ, Ranjith B, Jackson R, Wijeratne DT (2021) Cannabis and its derivatives for the use of motor symptoms in Parkinson\u2019s disease: a systematic review and meta-analysis. Ther Adv Neurol Disord 14. https:\/\/doi.org\/10.1177\/17562864211018561","DOI":"10.1177\/17562864211018561"},{"key":"564_CR104","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3233\/JPD-212923","volume":"12","author":"B Urbi","year":"2022","unstructured":"Urbi B, Corbett J, Hughes I et al (2022) Effects of cannabis in Parkinson\u2019s disease: a systematic review and meta-analysis. J Parkinsons Dis 12:495\u2013508. https:\/\/doi.org\/10.3233\/JPD-212923","journal-title":"J Parkinsons Dis"},{"key":"564_CR105","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1021\/cn200114w","volume":"3","author":"S Valdeolivas","year":"2012","unstructured":"Valdeolivas S, Satta V, Pertwee RG et al (2012) Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington\u2019s disease: role of CB1 and CB2 receptors. ACS Chem Nerosci 3:400\u2013406. https:\/\/doi.org\/10.1021\/cn200114w","journal-title":"ACS Chem Nerosci"},{"key":"564_CR106","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.2967\/JNUMED.110.077156","volume":"51","author":"K Van Laere","year":"2010","unstructured":"Van Laere K, Casteels C, Dhollander I et al (2010) Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo. J Nucl Med 51:1413\u20131417. https:\/\/doi.org\/10.2967\/JNUMED.110.077156","journal-title":"J Nucl Med"},{"key":"564_CR107","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1002\/MDS.20111","volume":"19","author":"K Venderov\u00e1","year":"2004","unstructured":"Venderov\u00e1 K, Ru\u017ei\u010dka E, Vor\u0159\u00eds\u0161ek V, Vi\u0161\u0148ovsk\u00fd P (2004) Survey on cannabis use in Parkinson\u2019s disease: subjective improvement of motor symptoms. Mov Disord 19:1102\u20131106. https:\/\/doi.org\/10.1002\/MDS.20111","journal-title":"Mov Disord"},{"key":"564_CR108","doi-asserted-by":"publisher","unstructured":"Watson KK, Bryan AD, Thayer RE et al (2022) Cannabis use and resting state functional connectivity in the aging brain. Front Aging Neurosci 14. https:\/\/doi.org\/10.3389\/FNAGI.2022.804890","DOI":"10.3389\/FNAGI.2022.804890"},{"key":"564_CR109","doi-asserted-by":"publisher","first-page":"e49965","DOI":"10.2196\/49965","volume":"7","author":"I Weber","year":"2024","unstructured":"Weber I, Zagona-Prizio C, Sivesind TE et al (2024) Oral Cannabidiol for seborrheic dermatitis in patients with Parkinson disease: randomized clinical trial. JMIR Dermatol 7:e49965. https:\/\/doi.org\/10.2196\/49965","journal-title":"JMIR Dermatol"},{"key":"564_CR110","doi-asserted-by":"publisher","unstructured":"Weinstein G, Sznitman SR (2020) The implications of late-life cannabis use on brain health: a mapping review and implications for future research. Ageing Res Rev 59. https:\/\/doi.org\/10.1016\/J.ARR.2020.101041","DOI":"10.1016\/J.ARR.2020.101041"},{"key":"564_CR111","doi-asserted-by":"publisher","unstructured":"Weston-Green K, Clunas H, Jimenez Naranjo C (2021) A review of the potential use of Pinene and linalool as terpene-based medicines for brain health: discovering novel therapeutics in the flavours and fragrances of cannabis. Front Psych 12. https:\/\/doi.org\/10.3389\/FPSYT.2021.583211","DOI":"10.3389\/FPSYT.2021.583211"},{"key":"564_CR112","doi-asserted-by":"publisher","unstructured":"Xiong Y, Lim CS (2021) Understanding the modulatory effects of Cannabidiol on Alzheimer\u2019s disease. Brain Sci 11. https:\/\/doi.org\/10.3390\/BRAINSCI11091211","DOI":"10.3390\/BRAINSCI11091211"},{"key":"564_CR113","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3233\/JPD-202260","volume":"11","author":"F Yenilmez","year":"2021","unstructured":"Yenilmez F, Fr\u00fcndt O, Hidding U, Buhmann C (2021) Cannabis in Parkinson\u2019s disease: the patients\u2019 view. J Parkinsons Dis 11:309\u2013321. https:\/\/doi.org\/10.3233\/JPD-202260","journal-title":"J Parkinsons Dis"},{"key":"564_CR114","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1080\/15504263.2019.1665218","volume":"16","author":"HB Yoo","year":"2020","unstructured":"Yoo HB, DiMuzio J, Filbey FM (2020) Interaction of cannabis use and aging: from molecule to mind. J Dual Diagn 16:140\u2013176. https:\/\/doi.org\/10.1080\/15504263.2019.1665218","journal-title":"J Dual Diagn"},{"key":"564_CR115","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1007\/S00417-021-05533-1","volume":"260","author":"O Zloto","year":"2022","unstructured":"Zloto O, Weisman A, Avisar I et al (2022) Medical cannabis oil for benign essential blepharospasm: a prospective, randomized controlled pilot study. Graefes Arch Clin Exp Ophthalmol 260:1707\u20131712. https:\/\/doi.org\/10.1007\/S00417-021-05533-1","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"564_CR116","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/J.SEIZURE.2019.03.003","volume":"67","author":"JP Z\u00f6llner","year":"2019","unstructured":"Z\u00f6llner JP, Noda AH, Rosenow F, Strzelczyk A (2019) Improving post-hypoxic myoclonus using cannabidiol. Seizure 67:38\u201339. https:\/\/doi.org\/10.1016\/J.SEIZURE.2019.03.003","journal-title":"Seizure"},{"key":"564_CR117","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1177\/0269881108096519","volume":"23","author":"AW Zuardi","year":"2009","unstructured":"Zuardi AW, Crippa JAS, Hallak JEC et al (2009) Cannabidiol for the treatment of psychosis in Parkinson\u2019s disease. J Psychopharmacol 23:979\u2013983. https:\/\/doi.org\/10.1177\/0269881108096519","journal-title":"J Psychopharmacol"}],"container-title":["Current Topics in Behavioral Neurosciences","Behavioral Impact of Cannabinoids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/7854_2024_564","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:14:49Z","timestamp":1777378489000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/7854_2024_564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9783032091321","9783032091338"],"references-count":117,"URL":"https:\/\/doi.org\/10.1007\/7854_2024_564","relation":{},"ISSN":["1866-3370","1866-3389"],"issn-type":[{"value":"1866-3370","type":"print"},{"value":"1866-3389","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"31 December 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}